Compliant Claims Marketing Rule
Educate on symptoms and evidence without promising prohibited treatment outcomes
- Difficulty
- Advanced
- Time to result
- ~ongoing to results
- Steps
- 6
- Confidence
- 93%
Berge presents marketing compliance as a line-by-line claims discipline rather than a vague intention to behave well. In his account, regenerative products sit under overlapping FDA and FTC scrutiny, with particular risk arising when a company markets a biologic as though it were an approved drug for a specific condition. The practical rule is to avoid guarantees and cure or treatment claims, use the narrower symptom language permitted to the business, and disclose material limitations such as lack of insurance coverage. Education, testimonials, and independent research can help customers understand the category, but they do not justify overstating certainty. Berge says his companies try to operate above the minimum because visibility in a regulated industry makes attempts to cut corners especially dangerous.
Origin
Extracted from Coffeez for Closers, where Berge explains the regulatory marketing constraints he has navigated while building regenerative-therapy companies.
Core principles
- 01Market within the language regulators permit
- 02Never turn observed outcomes into guarantees
- 03Educate customers without disguising material limitations
- 04Treat compliance as a continuing operating discipline
How to run it
- 1
Map the oversight
Identify which bodies regulate the product, the production process, and the marketing. Do not assume that being outside one product category means the offer is unregulated.
Pro tip Separate production requirements from advertising requirements.
Watch out Regulatory gray areas still carry enforcement risk.
- 2
Audit every outcome claim
Review copy for promises that a product will cure, eliminate, or treat a named condition. Remove guarantees and unsupported certainty.
Watch out A strong customer outcome does not automatically make the same result a permissible universal claim.
- 3
Use permitted language
Describe what the offer can address in the narrower terms allowed for the category. Keep wording accurate to the status of the product and evidence.
Pro tip Berge contrasts a treatment claim with language about addressing symptoms.
Watch out Do not use euphemisms to smuggle a guarantee back into the copy.
- 4
Disclose limitations
Tell customers material facts that affect their decision, including approval status and whether insurance is expected to cover the service. Make these disclosures part of education rather than an afterthought.
- 5
Support informed evaluation
Give prospects enough information to research and discuss the option without making the decision for them. Distinguish evidence and testimonials from guaranteed individual results.
Watch out Testimonials cannot safely be presented as promises.
- 6
Maintain the discipline
Recheck marketing as the company grows and enforcement changes. Train partners and salespeople to use the same compliant boundaries.
Pro tip Operate as though regulators already know the company and its public claims.
Watch out Growth raises visibility and the cost of inconsistent claims.
In the wild
Berge says a marketer should not guarantee that stem-cell therapy will completely eliminate osteoarthritis or present the biologic as an approved drug for that indication. He says his business instead uses language about addressing symptoms and is explicit that insurance will not cover the therapy.
→ The offer can still be explained while avoiding the guarantee and treatment framing Berge identifies as risky.
Common mistakes
Turning outcomes into guarantees
Reported success with previous customers does not justify promising the same result to everyone. Claims must preserve uncertainty.
Assuming gray means unregulated
Berge describes oversight of tissue handling, laboratories, and marketing even though the products are not FDA-approved drugs. Map the actual boundaries instead of treating ambiguity as freedom.
Hiding material costs
Customers should be told when insurance will not cover the therapy. Transparency is part of compliant education and informed consent.
Is it for you?
Best for
It is best for companies marketing biologics or other high-scrutiny products whose claims are constrained by regulators.
Not ideal for
It is not a substitute for qualified legal, medical, or regulatory review of a specific campaign.
From the transcript
“It's really the marketing side that you have to be careful of.”
“We have to say things like this can address the symptoms of your your osteoarthritis.”
“we're very upfront about that”
From the episode
Stem Cells, Exosomes & the Future of Recovery ft. Seth Berge I Coffeez with Joe Shalaby
Seth Berge